ProKidney Corp.
PROKAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 4, 2024 | Bank of America Securities | Jason Gerberry | $3.00(+25%) | $2.40 | TheFly |
| Sep 3, 2024 | BTIG | Justin Zelin | $5.00(+108%) | $2.40 | StreetInsider |
| Jun 10, 2024 | Jefferies | Kelly Shi | $6.00(+99%) | $3.02 | StreetInsider |
| May 28, 2024 | BTIG | Justin Zelin | $6.00(+62%) | $3.71 | StreetInsider |
| Dec 21, 2022 | Jefferies | $15.00(+105%) | $7.30 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Citigroup | maintain | Buy | Oct 28, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 18, 2026 |
| UBS | maintain | Buy | Jul 15, 2025 |
| Guggenheim | maintain | Buy | Jul 14, 2025 |
| Citigroup | maintain | Buy | Jul 9, 2025 |
| B of A Securities | downgrade | Neutral →Underperform | Jun 30, 2025 |
| B of A Securities | maintain | Neutral | Sep 4, 2024 |
| Jefferies | maintain | Buy | Jun 10, 2024 |
| B of A Securities | maintain | Neutral | May 29, 2024 |
| B of A Securities | downgrade | Buy →Neutral | Jan 2, 2024 |
| Jefferies | maintain | Buy | Dec 21, 2022 |
| Morgan Stanley | maintain | Equal Weight | Nov 10, 2022 |
| UBS | maintain | Buy | Oct 18, 2022 |
| Citigroup | maintain | Buy | Oct 14, 2022 |
| Evercore ISI Group | maintain | Outperform | Sep 2, 2022 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 10, 2026 | $-0.15 | $-0.14 | $150.0K | $186.3K |
| May 15, 2026 | $-0.14 | $-0.13 | $226.0K | $100.3K |
| Mar 18, 2026 | $-0.14 | $-0.16 | $223.0K | $600.00 |
| Nov 10, 2025 | $-0.12 | $-0.12 | $217.0K | — |
| Aug 12, 2025 | $-0.13 | $-0.14 | $221.0K | $44.3K |
| May 12, 2025 | $-0.13 | $-0.16 | $230.0K | — |
| Mar 17, 2025 | $-0.17 | $-0.14 | $76.0K | — |
| Nov 12, 2024 | $-0.14 | $-0.14 | — | — |
News
ProKidney NASDAQ: PROK said it remains on track to report top-line results from the interim analysis of its Phase III PROACT 1 study in the second quarter of 2027, following stronger-than-expected patient recruitment for its investigational autologous cell therapy, rilparencel.
ProKidney Corp. (PROK) Discusses Rilparencel Mechanism and Role in Advanced Chronic Kidney Disease Transcript
WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 27, 2026, at 10:30 AM ET. To register, click here.
Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencel One clinical abstract presents a new pooled Phase 2 analysis of patients meeting key PROACT 1 inclusion criteria that continues to indicate a strong safety profile and kidney function stabilization in patients with advanced CKD and type 2 diabetes mellitus WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKi…
WINSTON-SALEM, N.C., Oct. 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that the Company will present eight abstracts, including one oral presentation, at the upcoming American Society of Nephrology's (ASN) Kidney Week being held from October 21-25, 2026, in Denver, CO.
ProKidney (NASDAQ: PROK - Get Free Report) and Pyxis Oncology (NASDAQ: PYXS - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability. Analyst Recommendations This is a breakdown of recent
Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
ProKidney Corp. is a single-asset biotech with a dwindling cash position and an unproven lead therapy, rilparencel. Phase 2 data for rilparencel is weak, with confounding factors and no robust evidence of efficacy; Phase 3 PROACT data in 2027 is pivotal. PROK's cash runway extends only into mid-2027, with just $181.6M remaining and ongoing high cash burn, raising 'going concern' doubts.
ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.